Skip to main content
Premium Trial:

Request an Annual Quote

Precision BioSciences Files Fourth Patent Lawsuit Against Cellectis

NEW YORK (GenomeWeb News) – Precision BioSciences today said it has filed a fourth lawsuit against Cellectis and a number of its affiliates alleging patent infringement.

The company filed its lawsuit in US District Court for the Eastern District of North Carolina claiming Cellectis infringes on US Patent No. 8,124,369, which relates to Precision Bio's Directed Nuclease Editor genome engineering technology.

The Research Triangle Park, N.C.-based genetic engineering company is asking for monetary damages, a permanent injunction against Cellectis from making, using, selling, offering for sale, or importing infringing engineered meganucleases in the US.

Precision Bio filed two lawsuits against the French firm last week as well as one in the fall.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.